囊性纤维化患者分离的洋葱伯克霍尔德菌复合体对头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦的敏感性。
Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.
机构信息
Department Microbiology, National Reference Center for Burkholderia Cepacia Complex (NRC), Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium
Department Microbiology, National Reference Center for Burkholderia Cepacia Complex (NRC), Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
出版信息
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00590-18. Print 2018 Sep.
Abstract
We tested the susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole. Eighty-one and 63% of all BCC strains were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. For temocillin, ceftazidime, piperacillin-tazobactam, and meropenem, at least 50% of the strains were susceptible. seems to be more resistant than other BCC species.
摘要
我们测试了头孢他啶-阿维巴坦和头孢噻肟-他唑巴坦以及其他 13 种抗生素对 2012 年以来从囊性纤维化患者中分离出的 91 株复杂（BCC）菌株的敏感性。最高的敏感性（82%）被发现为复方磺胺甲噁唑。81%和 63%的所有 BCC 菌株对头孢他啶-阿维巴坦和头孢噻肟-他唑巴坦分别敏感。对于替莫西林、头孢他啶、哌拉西林-他唑巴坦和美罗培南，至少有 50%的菌株敏感。与其他 BCC 物种相比，似乎更具有耐药性。
相似文献
1
Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.囊性纤维化患者分离的洋葱伯克霍尔德菌复合体对头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦的敏感性。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00590-18. Print 2018 Sep.
2
"Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Complex and Cystic Fibrosis Isolates.“切换伙伴”：哌拉西林-他唑巴坦对多药耐药复杂菌和囊性纤维化分离株具有强大的联合作用。
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00181-19. Print 2019 Aug.
3
In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.七种β-内酰胺类药物（包括头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦）对从囊性纤维化患者中分离出的洋葱伯克霍尔德菌复合体、唐菖蒲伯克霍尔德菌及其他非发酵革兰氏阴性杆菌的体外活性。
J Antimicrob Chemother. 2019 Feb 1;74(2):525-528. doi: 10.1093/jac/dky423.
4
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.耐哌拉西林/他唑巴坦铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药性的系统进化分析。
Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.
5
Susceptibility of Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients.复杂感染对头孢他啶/阿维巴坦和囊性纤维化患者标准治疗药物的敏感性。
Microb Drug Resist. 2022 May;28(5):545-550. doi: 10.1089/mdr.2021.0353. Epub 2022 May 5.
6
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.战胜一种极耐药（XDR）病原体：阿维巴坦恢复了囊性纤维化患者分离出的洋葱伯克霍尔德菌复合体对头孢他啶的敏感性。
ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.
7
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.评估头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦对来自卡塔尔的多重耐药铜绿假单胞菌分离株的体外活性。
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504. doi: 10.1093/jac/dkz379.
8
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).比较头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对 2017-2018 年美国医疗中心住院肺炎患者分离的革兰氏阴性菌的体外活性。
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114833. doi: 10.1016/j.diagmicrobio.2019.05.005. Epub 2019 May 10.
9
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.碳青霉烯类耐药肠杆菌科细菌和铜绿假单胞菌中头孢他啶-阿维巴坦和头孢唑南-他唑巴坦药敏检测方法的验证。
J Clin Microbiol. 2018 Jan 24;56(2). doi: 10.1128/JCM.01093-17. Print 2018 Feb.
10
Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.头孢他洛酯-他唑巴坦和其他抗菌药物对洋葱伯克霍尔德菌复合体和脆弱拟杆菌的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00766-17. Print 2017 Sep.
引用本文的文献
1
In vitro susceptibility of to ceftazidime-avibactam: A systematic review.对头孢他啶-阿维巴坦的体外敏感性：一项系统评价。
New Microbes New Infect. 2025 May 28;66:101601. doi: 10.1016/j.nmni.2025.101601. eCollection 2025 Aug.
2
Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.在使用头孢他啶-阿维巴坦治疗期间获得革兰氏阴性菌的患者的临床特征
Infect Dis Ther. 2025 May;14(5):1027-1042. doi: 10.1007/s40121-025-01126-1. Epub 2025 Apr 2.
3
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options.罕见或不常见的非发酵革兰氏阴性菌：治疗方法与抗生素治疗选择
Antibiotics (Basel). 2025 Mar 16;14(3):306. doi: 10.3390/antibiotics14030306.
4
The in vitro synergistic and antibiofilm activity of Ceftazidime/avibactam against Achromobacter species recovered from respiratory samples of cystic fibrosis patients.头孢他啶/阿维巴坦对从囊性纤维化患者呼吸道样本中分离出的无色杆菌属细菌的体外协同及抗生物膜活性。
Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):587-596. doi: 10.1007/s10096-024-05017-0. Epub 2024 Dec 20.
5
Mutations Affecting Cellular Levels of Cobalamin (Vitamin B) Confer Tolerance to Bactericidal Antibiotics in .影响钴胺素（维生素 B）细胞水平的突变赋予 对杀菌抗生素的耐受性。
J Microbiol Biotechnol. 2024 Aug 28;34(8):1609-1616. doi: 10.4014/jmb.2406.06028. Epub 2024 Jul 11.
6
complex in cystic fibrosis: critical gaps in diagnosis and therapy.囊性纤维化中的复杂性：诊断和治疗中的关键差距。
Ann Med. 2024 Dec;56(1):2307503. doi: 10.1080/07853890.2024.2307503. Epub 2024 Jan 23.
7
Susceptibility of Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey.从囊性纤维化患者中分离出的 种属的易感性：一项 6 年调查。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0037923. doi: 10.1128/aac.00379-23. Epub 2023 Jun 13.
8
Antibacterial Activity of a Natural Clay Mineral against Complex and Other Bacterial Pathogens Isolated from People with Cystic Fibrosis.一种天然粘土矿物对从囊性纤维化患者中分离出的复杂及其他细菌病原体的抗菌活性。
Microorganisms. 2023 Jan 6;11(1):150. doi: 10.3390/microorganisms11010150.
9
The Class A β-Lactamase Produced by Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States.该菌种产生的A类β-内酰胺酶会降低替比培南对一组来自美国的分离株的效力。
Antibiotics (Basel). 2022 May 17;11(5):674. doi: 10.3390/antibiotics11050674.
10
Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.亚胺培南-雷巴他定对多药和广泛耐药洋葱伯克霍尔德菌复合群和格劳氏伯克霍尔德菌的活性。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0133221. doi: 10.1128/AAC.01332-21. Epub 2021 Aug 9.
本文引用的文献
1
Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.头孢他洛酯-他唑巴坦和其他抗菌药物对洋葱伯克霍尔德菌复合体和脆弱拟杆菌的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00766-17. Print 2017 Sep.
2
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.头孢洛扎/他唑巴坦对来自不列颠群岛的监测菌及“问题”肠杆菌科细菌、铜绿假单胞菌和非发酵菌的活性。
J Antimicrob Chemother. 2017 Aug 1;72(8):2278-2289. doi: 10.1093/jac/dkx136.
3
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.战胜一种极耐药（XDR）病原体：阿维巴坦恢复了囊性纤维化患者分离出的洋葱伯克霍尔德菌复合体对头孢他啶的敏感性。
ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub 2017 Mar 30.
4
Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against complex species.β-内酰胺酶抑制剂对β-内酰胺类抗生素针对复杂菌属的体外活性的影响
Antimicrob Resist Infect Control. 2016 Nov 16;5:44. doi: 10.1186/s13756-016-0142-3. eCollection 2016.
5
Combination antimicrobial susceptibility testing of Burkholderia cepacia complex: significance of species.洋葱伯克霍尔德菌复合体的联合抗菌药敏试验：种属的意义。
Int J Antimicrob Agents. 2016 Nov;48(5):521-527. doi: 10.1016/j.ijantimicag.2016.07.020. Epub 2016 Sep 12.
6
In vitro susceptibility of Burkholderia cepacia complex isolates: Comparison of disk diffusion, Etest®, agar dilution, and broth microdilution methods.洋葱伯克霍尔德菌复合体分离株的体外药敏试验：纸片扩散法、Etest法、琼脂稀释法和肉汤微量稀释法的比较
Diagn Microbiol Infect Dis. 2016 Dec;86(4):422-427. doi: 10.1016/j.diagmicrobio.2016.08.015. Epub 2016 Aug 28.
7
Antibiotic resistance in Burkholderia species.伯克霍尔德菌属的抗生素耐药性。
Drug Resist Updat. 2016 Sep;28:82-90. doi: 10.1016/j.drup.2016.07.003. Epub 2016 Jul 30.
8
Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.对患有囊性纤维化且肺部病情加重的患者使用抗生素治疗洋葱伯克霍尔德菌复合体。
Cochrane Database Syst Rev. 2016 Jan 20;2016(1):CD009529. doi: 10.1002/14651858.CD009529.pub3.
9
Successful Use of Temocillin as Salvage Therapy for Cervical Osteomyelitis Secondary to Multidrug-Resistant Burkholderia cepacia.
J Pediatric Infect Dis Soc. 2014 Mar;3(1):77-80. doi: 10.1093/jpids/pis110. Epub 2013 Jan 8.
10
Cell Wall Recycling-Linked Coregulation of AmpC and PenB β-Lactamases through ampD Mutations in Burkholderia cenocepacia.洋葱伯克霍尔德菌中通过ampD突变实现的细胞壁循环相关的AmpC和PenBβ-内酰胺酶共调控
Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10. doi: 10.1128/AAC.01068-15. Epub 2015 Sep 28.
Zotero 插件